Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Preprint in English | medRxiv | ID: ppmedrxiv-21253946

ABSTRACT

Mutations at both the receptor-binding domain (RBD) and the amino (N)-terminal domain (NTD) of the SARS-CoV-2 Spike (S) glycoprotein can alter its antigenicity and promote immune escape. We identified that SARS-CoV-2 lineages circulating in Brazil with mutations of concern in the RBD independently acquired convergent deletions and insertions in the NTD of the S protein, which altered the NTD antigenic-supersite and other predicted epitopes at this region. These findings support that the ongoing widespread transmission of SARS-CoV-2 in Brazil is generating new viral lineages that might be more resistant to neutralization than parental variants of concern.

2.
Nat Commun ; 9(1): 2441, 2018 06 22.
Article in English | MEDLINE | ID: mdl-29934593

ABSTRACT

Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ∆TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.


Subject(s)
Antigens, Viral/genetics , Drug Design , Viral Vaccines/immunology , Zika Virus Infection/prevention & control , Zika Virus/immunology , Adenoviridae/genetics , Animals , Antibody-Dependent Enhancement/immunology , Antigens, Viral/immunology , Dengue Virus/immunology , Disease Models, Animal , Female , Genetic Vectors/genetics , Humans , Immunogenicity, Vaccine , Mice , Mice, Inbred BALB C , Mice, Inbred ICR , Pan troglodytes/virology , Protein Domains/genetics , Protein Domains/immunology , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Viral Vaccines/administration & dosage , Viral Vaccines/genetics , Zika Virus/genetics , Zika Virus Infection/immunology , Zika Virus Infection/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...